We are pleased to announce Septerna has been named one of #10StartupsToWatch by C&EN (Chemical & Engineering News). It’s an honor to receive this recognition and to be included among such incredible companies doing groundbreaking work: bit.ly/3sqq12R #biotech #innovation

It’s #ThyroidEyeDisease (TED) Awareness Week, an autoimmune disorder for which treatment options are limited. Septerna is making progress toward a potentially disease-modifying therapy targeting the thyroid stimulating hormone receptor (TSHR), a #GPCR involved in TED.

George Xu, Senior Director of Corporate Development & Portfolio Strategy, comments on growing interest #GPCRs & his excitement for the advancements made possible through Septerna's groundbreaking platform. We are doing something quite different here. #drugdiscovery

Season's Greetings from Septerna! May your holiday season be merry and bright. #SeasonsGreetings #HappyHolidays

Over the next month our management team will be present and participate at multiple investor and industry conferences. We look forward to seeing you if you’re attending! bit.ly/3UMlPWQ

This month we added five new amazing employees to the team in the areas of Quality Assurance, Facilities, Disease Biology, CMC and DMPK. Welcome to all and we look forward to your contributions!

We are pleased to present data from our #GPCR drug discovery engine at #ENDO2024. These results validate our approach & reaffirm our dedication to deliver transformative therapies to patients. Attending ENDO? Join us to learn more: bit.ly/4dQddFF

Today at #ENDO2024 we presented preclinical data from our PTH1R and TSHR programs which highlight the potential of our GPCR platform to discover drugs for endocrine disorders. Learn more: bit.ly/3yLu7p4 #drugdiscovery #endocrinology

We are pleased to welcome our wonderful group of Summer interns, who will be working with us in medicinal chemistry, people and culture, protein science and platform technology. We look forward to seeing the valuable contributions they will make to our team.

We’re thrilled to announce that Septerna is now publicly traded on NASDAQ under $SEPN! A huge thanks to our team, investors, and partners who made this moment possible. Here's to unlocking the potential of GPCR-targeted therapies. #GPCRScience #NASDAQ

We’re thrilled to announce Gil Labrucherie has joined Septerna as Chief Financial Officer! With 25+ years of senior leadership in biopharma and technology finance and legal roles, he will be instrumental as we advance SEP-786 and our GPCR pipeline. bit.ly/403wdKT $SEPN

Join us this afternoon for Septerna’s #JPM25 podium presentation, in person or via webcast! We’re excited to share our progress in unlocking GPCR therapeutic potential for patient-focused treatments. bit.ly/3DTBc9C #BiotechInnovation #GPCRScience